SINGU acquires Synbiotix to expand healthcare facilities management capabilities

SINGU, a top European provider of cloud-based software for property operations and facility management has acquired UK-based Synbiotix. 

The acquisition strengthens SINGU’s presence in the United Kingdom and expands its healthcare capabilities, with a particular focus on supporting the operational and regulatory needs of the UK’s National Health Service (NHS).

Synbiotix is an established provider of specialised software solutions for healthcare facilities management with a focus on catering, compliance, infection prevention and control (IPC), as well as audit and governance processes. 

Its solutions support healthcare organisations in managing regulatory requirements efficiently, reducing operational risk and improving patient safety. 

Through the acquisition, Synbiotix adds a critical healthcare-specific component to SINGU’s building operations platform, and complements the existing Micad solutions.

Following SINGU’s acquisition of Micad in 2025, which expanded its space and asset management capabilities, the addition of Synbiotix further strengthens the Group’s integrated facilities management offering. 

Together, SINGU provides the core CAFM and maintenance platform, Micad adds space, compliance, and asset intelligence, and Synbiotix delivers specialist digital tools for a complete facilities management operation. Combined, these solutions enable healthcare organisations to manage facilities, catering, and operational requirements through a single, coordinated technology environment.

Paweł Malon, Group CEO, told That's Health: “The acquisition of Synbiotix significantly strengthens our position in the healthcare market and further establishes SINGU as a leading European provider of property operations software. 

"We are committed to building an integrated, end-to-end platform that drives value across complex property operations. I look forward to working with Mark Edell and his team to drive operational excellence and improve patient experience.”

Synbiotix will continue to operate within the SINGU Group, ensuring continuity for existing customers while gaining access to a scalable, cloud-based platform designed to meet the evolving needs of the healthcare sector. 

The integration also creates new opportunities to develop Synbiotix’s solutions within a broader ecosystem and extend them to the existing Micad customer base—supporting seamless operations across more than 200 NHS Trusts and many other clients.

“Joining SINGU represents a strategic milestone for Synbiotix. We contribute deep healthcare expertise and many years of experience working with the NHS, while benefiting from the technological strength and scalability of the SINGU platform. This combination creates new opportunities to further develop our solutions and deliver even greater value to healthcare organisations,” added Mark Edell, Managing Director of Synbiotix.

The acquisition of Synbiotix forms part of SINGU’s continued growth strategy in Europe and underlines the strategic importance of the healthcare sector to the Group. It follows SINGU’s acquisition of Micad and net-haus in 2025, and reflects a targeted buy-and-build approach aimed at creating a leading, vertically integrated platform for mission-critical applications across property operations.

For more information, visit SINGU.com.